Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Psychopharmacology (Oxford, England)|October 15, 2009
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophreniaJoris Berwaerts, Adriaan Cleton, Stefaan Rossenu, et al.
British Journal of Clinical Pharmacology|April 4, 2026
A phase 1 evaluation of inhaled oxytocin: Physiologically-based pharmacokinetic model informed dosing of a novel heat-stable oxytocin delivery systemPete Lambert, Carl M J Kirkpatrick, Rory Marriott, et al.
Expert Review of Clinical Pharmacology|January 8, 2025
Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhageC C Lee, Luther Gwaza, Karin Rombouts, et al.
Clinical Therapeutics|September 11, 2007
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disordersMichael G Aman, Alexander A Vinks, Bart Remmerie, et al.
Advances in Therapy|December 14, 2019
Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein InhibitorBart Remmerie, Maarten van den Boer, Thomas Van Looy, et al.
BMC Psychiatry|March 30, 2012
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaDanielle Coppola, Yanning Liu, Srihari Gopal, et al.
Journal of Clinical Pharmacology|August 29, 2009
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseSandra Boom, Krishna Talluri, Luc Janssens, et al.
Journal of Clinical Pharmacology|July 21, 2015
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyPaulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.
JAMA Psychiatry|March 31, 2015
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical TrialJoris Berwaerts, Yanning Liu, Srihari Gopal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2020
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b StudyFederico Martinón-Torres, Sarah Rusch, Dymphy Huntjens, et al.
Pageof 4